Recently, the microbiome has been shown to influence the type and intensity of the body’s anti-tumour immune response. Researchers are showing significant differences in cancer patient microbiomes, correlating with treatment response to CTLA-4, PD-1 and PD-L1 immunotherapy.
Join us, for CSM’s final exciting seminar of 2019!
For this seminar we have Dr Ashwini Chand. – Lab Head of Cancer therapeutics Development at the Olivia Newton-John Cancer Research Institute. Her research is centered on the biology of gastrointestinal cancers and understanding the importance of a transcription factor STAT3 in regulating the intestinal barrier integrity by acting on the intestinal epithelial cells.
Utilising an inflammation (colitis) driven model, Dr Chand is investigating whether the impairment of the barrier function would affect the microbiome dynamics and contribute to a more aggravated GI cancer phenotype.
Her teams work is to attempt to enhance epithelial-mediated repair of the gut in chronic inflammation scenarios – to aid current efforts of microbiome rebalance (as a preventative and treatment ) in inflammation driven colorectal cancer. Her team couples an extensive knowledge of inflammatory mediators to identify drugs that are already in clinical use and may be repurposed as cancer therapeutics. In this way, Dr Chand’s team is making discoveries that will contribute to more efficient emergence of breakthrough cancer treatments.
Refreshments following the seminar catered by The Loft!
No responses yet